Frontier Biotechnologies Inc.

Frontier Biotechnologies Inc.


Company description

Frontier Biotechnologies Inc. is a research-based pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing significant unmet medical needs. - Its lead product candidate ALBUVIRTIDE, a novel long-acting anti-HIV agent. - The second lead drug candidate AB001 is a third generation topical patch for the management of pain and inflammation, and a phase 2 clinical trial of AB001 for the treatment of chronic low back pain was successfully completed in the US.  - Frontier Biotechnologies, Inc., announced it has signed an agreement with The Rockefeller University of the US for the worldwide license for combining 3BNC117, a novel broad-spectrum HIV neutralizing antibody, with ALBUVIRTIDE for the treatment and prophylaxis of HIV infection and AIDS.

Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Antibodies |Biochemicals |Other APIs More

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 92B35NEP See our Exhibitor Profile   See full Exhibitor List
Frontier Biotechnologies Inc.

Contact information




View all contact information